Business
Vistagen Appoints Elissa Cote as Chief Corporate Development Officer
SOUTH SAN FRANCISCO, Calif., June 25, 2025--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen’s pherine platform toward potential commercial launc
About this update from Vistagen Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":542,"url":"https://media.zenfs.com/en/business-wire.com/5a3b7241d8093bf773a26c0ff8b058f0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3lKm3aJ2EWgM3EQdvFI8ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5a3b7241d8093bf773a26c0ff8b058f0","width":960,"height":260},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/kk.wPDC_5kcYQEDAahOQeQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02NTA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5a3b7241d8093bf773a26c0ff8b058f0","width":1200,"height":325}},"lazy":false},{"type":"text","content":"Accomplished biopharma executive brings nearly 30 years of experience in business development, enterprise strategy, and global partnerships to her role","length":151,"tagName":"p","attribs":{}},{"type":"text","content":"Ms. Cote to help drive the strategic positioning of Vistagen’s clinical-stage pipeline, which includes five novel intranasal pherine candidates targeting six highly prevalent and underserved disorders","length":200,"tagName":"p","attribs":{}},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., June 25, 2025--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines, today announced the appointment of Elissa Cote as Chief Corporate Development Officer. In this role, Ms. Cote will lead the evaluation of strategic opportunities to advance Vistagen’s pherine platform toward potential commercial launches and cultivate prospective strategic partnerships for the Company.","length":586,"tagName":"p"},{"type":"text","content":""Elissa is a highly respected executive with a strong track record of driving growth, building partnerships, and developing commercial strategies for biotech and pharmaceutical companies," said Shawn Singh, President and Chief Executive Officer. "We’re excited to welcome Elissa at such a pivotal moment for our business. Her deep strategic and transactional expertise strengthen our team, and she will play a key leadership role as we continue to advance our programs."","le...